Colorado is currently home to 1795 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053
Recruiting
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2025
Locations: GSK Investigational Site, Lakewood, Colorado
Conditions: Asthma
Register for Updates
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197
Recruiting
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Local Institution - 0008, Aurora, Colorado
Conditions: Advanced Solid Tumors
Register for Updates
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686
Recruiting
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/08/2025
Locations: National Jewish Medical and Research Center, Denver, Colorado
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Research Site, Aurora, Colorado
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
05/08/2025
Locations: Children'S Hospital Colorado, Aurora, Colorado
Conditions: NonSegmental Vitiligo
Register for Updates
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
NCT06512883
Recruiting
The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/08/2025
Locations: Research Site, Aurora, Colorado
Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Register for Updates
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806
Recruiting
This phase II trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910
Recruiting
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2025
Locations: Peak Gastroenterology Associates, Colorado Springs, Colorado
Conditions: Crohn's Disease
Register for Updates
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Sarah Cannon Research Institue At Healthone, Denver, Colorado
Conditions: Solid Tumors
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/08/2025
Locations: University of Colorado - Anschutz Medical Campus- Site Number : 8401001, Aurora, Colorado
Conditions: Multiple Sclerosis
Register for Updates
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
NCT06050252
Recruiting
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectable). Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Resectable Intrahepatic Cholangiocarcinoma
Register for Updates
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080
Recruiting
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/08/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Large B-Cell Lymphoma
Register for Updates